Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Cost Curtailment Policy Should Now Target Hospitalization: JHEF Seminar
February 5, 2001
-
COMMENTARY -1-
February 5, 2001
-
ARCHIVE ON THE MOVE
February 5, 2001
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 5, 2001
-
COMMENTARY -2-
February 5, 2001
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF
February 5, 2001
-
ARCHIVE Kirin Obtains Rights to Cerus's Allogeneic Cellular Immune Therapy Technology
February 5, 2001
-
ARCHIVE Takara Obtains Marketing Rights for Analysis Services from GeneFormatics
February 5, 2001
-
ARCHIVE NHI Prices of 12 New Ingredients Including Tamiflu, Relenza Approved
February 5, 2001
-
ARCHIVE Kissei, Teikoku Hormone to Codevelop Threatened Premature Delivery Treatment
February 5, 2001
-
ARCHIVE Peak Sales of 5 New Drugs Expected to Exceed \10 Bil.: Chuikyo
February 5, 2001
-
ARCHIVE Proposed Human Genome Research GL Explained by Kyoto Univ. Professor
February 5, 2001
-
ARCHIVE Phase III Comparative Study on Progressive Lung Cancer Begins
January 29, 2001
-
ARCHIVE Toho Ties Up with Tsuruhara Yoshii in Kumamoto
January 29, 2001
-
ARCHIVE Overall Mortality Increases at Total Cholesterol of 180 mg/dl or Less
January 29, 2001
-
ARCHIVE Santen Agrees with Nippon Organon to Develop, Manufacture, Market Glaucoma Treatment
January 29, 2001
-
ARCHIVE Novartis 5-Generation Campaign Recruits 378 Families
January 29, 2001
-
ARCHIVE Sankyo Completes Purchase of Sankyo Parke Davis Stocks from Pfizer
January 29, 2001
-
ARCHIVE WHO GLs for Allergic Rhinitis Introduced at UCB Symposium
January 29, 2001
-
ARCHIVE Kuraya Sanseido Aims at Sales of \1.5 Trillion in Next Stage
January 29, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…